Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 64 entries
Sorted by: Best Match Show Resources per page
Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Signoretti S, Flaifel A, Chen YB, Reuter VE.
PMID: 30372384
J Clin Oncol. 2018 Oct 29;JCO2018792259. doi: 10.1200/JCO.2018.79.2259. Epub 2018 Oct 29.

Renal cell carcinoma (RCC) is not a single entity but includes various tumor subtypes that have been identified on the basis of either characteristic pathologic features or distinctive molecular changes. Clear cell RCC is the most common type of...

Cite
Signoretti S, Flaifel A, Chen YB, et al. Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers. J Clin Oncol. 2018;JCO2018792259doi: 10.1200/JCO.2018.79.2259.
Signoretti, S., Flaifel, A., Chen, Y. B., & Reuter, V. E. (2018). Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2018792259. https://doi.org/10.1200/JCO.2018.79.2259
Signoretti, Sabina, et al. "Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. (2018): JCO2018792259. doi: https://doi.org/10.1200/JCO.2018.79.2259
Signoretti S, Flaifel A, Chen YB, Reuter VE. Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers. J Clin Oncol. 2018 Oct 29;JCO2018792259. doi: 10.1200/JCO.2018.79.2259. Epub 2018 Oct 29. PMID: 30372384; PMCID: PMC6299340.
Copy Download .nbib Format: NLM
Titanium Dioxide-Based Nanocomposites for Enhanced Gas-Phase Photodehydrogenation.

Materials (Basel, Switzerland)

Zanardo D, Ghedini E, Menegazzo F, Cattaruzza E, Manzoli M, Cruciani G, Signoretto M.
PMID: 31547485
Materials (Basel). 2019 Sep 23;12(19). doi: 10.3390/ma12193093.

Light-driven processes can be regarded as a promising technology for chemical production within the bio-refinery concept, due to the very mild operative conditions and high selectivity of some reactions. In this work, we report copper oxide (CuO)-titanium dioxide (TiO

Cite
Zanardo D, Ghedini E, Menegazzo F, et al. Titanium Dioxide-Based Nanocomposites for Enhanced Gas-Phase Photodehydrogenation. Materials (Basel). 2019;12(19)doi: 10.3390/ma12193093.
Zanardo, D., Ghedini, E., Menegazzo, F., Cattaruzza, E., Manzoli, M., Cruciani, G., & Signoretto, M. (2019). Titanium Dioxide-Based Nanocomposites for Enhanced Gas-Phase Photodehydrogenation. Materials (Basel, Switzerland), 12(19), . https://doi.org/10.3390/ma12193093
Zanardo, Danny, et al. "Titanium Dioxide-Based Nanocomposites for Enhanced Gas-Phase Photodehydrogenation." Materials (Basel, Switzerland) vol. 12,19 (2019). doi: https://doi.org/10.3390/ma12193093
Zanardo D, Ghedini E, Menegazzo F, Cattaruzza E, Manzoli M, Cruciani G, Signoretto M. Titanium Dioxide-Based Nanocomposites for Enhanced Gas-Phase Photodehydrogenation. Materials (Basel). 2019 Sep 23;12(19). doi: 10.3390/ma12193093. PMID: 31547485; PMCID: PMC6804072.
Copy Download .nbib Format: NLM
Toothbrushes may convey bacteria to the cystic fibrosis lower airways.

Journal of oral microbiology

Passarelli Mantovani R, Sandri A, Boaretti M, Grilli A, Volpi S, Melotti P, Burlacchini G, Lleò MM, Signoretto C.
PMID: 31489126
J Oral Microbiol. 2019 Aug 07;11(1):1647036. doi: 10.1080/20002297.2019.1647036. eCollection 2019.

Recent findings indicate that the oral cavity acts as a bacterial reservoir and might contribute to the transmission of bacteria to the lower airways. Control of a potentially pathogenic microbiota might contribute to prevent the establishment of chronic infection...

Cite
Passarelli Mantovani R, Sandri A, Boaretti M, et al. Toothbrushes may convey bacteria to the cystic fibrosis lower airways. J Oral Microbiol. 2019;11(1):1647036doi: 10.1080/20002297.2019.1647036.
Passarelli Mantovani, R., Sandri, A., Boaretti, M., Grilli, A., Volpi, S., Melotti, P., Burlacchini, G., Lleò, M. M., & Signoretto, C. (2019). Toothbrushes may convey bacteria to the cystic fibrosis lower airways. Journal of oral microbiology, 11(1), 1647036. https://doi.org/10.1080/20002297.2019.1647036
Passarelli Mantovani, Rebeca, et al. "Toothbrushes may convey bacteria to the cystic fibrosis lower airways." Journal of oral microbiology vol. 11,1 (2019): 1647036. doi: https://doi.org/10.1080/20002297.2019.1647036
Passarelli Mantovani R, Sandri A, Boaretti M, Grilli A, Volpi S, Melotti P, Burlacchini G, Lleò MM, Signoretto C. Toothbrushes may convey bacteria to the cystic fibrosis lower airways. J Oral Microbiol. 2019 Aug 07;11(1):1647036. doi: 10.1080/20002297.2019.1647036. eCollection 2019. PMID: 31489126; PMCID: PMC6713191.
Copy Download .nbib Format: NLM
KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1.

Cancer immunology research

Bhatt RS, Berjis A, Konge JC, Mahoney KM, Klee AN, Freeman SS, Chen CH, Jegede OA, Catalano PJ, Pignon JC, Sticco-Ivins M, Zhu B, Hua P, Soden J, Zhu J, McDermott DF, Arulanandam AR, Signoretti S, Freeman GJ.
PMID: 33229411
Cancer Immunol Res. 2021 Feb;9(2):156-169. doi: 10.1158/2326-6066.CIR-20-0315. Epub 2020 Nov 23.

Blockade of the PD1 pathway is a broadly effective cancer therapy, but additional immune-inhibitory pathways contribute to tumor immune evasion. HERV-H LTR-associating 2 (HHLA2; also known as B7H5 and B7H7) is a member of the B7 family of immunoregulatory...

Cite
Bhatt RS, Berjis A, Konge JC, et al. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Cancer Immunol Res. 2020;9(2):156-169doi: 10.1158/2326-6066.CIR-20-0315.
Bhatt, R. S., Berjis, A., Konge, J. C., Mahoney, K. M., Klee, A. N., Freeman, S. S., Chen, C. H., Jegede, O. A., Catalano, P. J., Pignon, J. C., Sticco-Ivins, M., Zhu, B., Hua, P., Soden, J., Zhu, J., McDermott, D. F., Arulanandam, A. R., Signoretti, S., & Freeman, G. J. (2021). KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Cancer immunology research, 9(2), 156-169. https://doi.org/10.1158/2326-6066.CIR-20-0315
Bhatt, Rupal S, et al. "KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1." Cancer immunology research vol. 9,2 (2021): 156-169. doi: https://doi.org/10.1158/2326-6066.CIR-20-0315
Bhatt RS, Berjis A, Konge JC, Mahoney KM, Klee AN, Freeman SS, Chen CH, Jegede OA, Catalano PJ, Pignon JC, Sticco-Ivins M, Zhu B, Hua P, Soden J, Zhu J, McDermott DF, Arulanandam AR, Signoretti S, Freeman GJ. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Cancer Immunol Res. 2021 Feb;9(2):156-169. doi: 10.1158/2326-6066.CIR-20-0315. Epub 2020 Nov 23. PMID: 33229411; PMCID: PMC8284010.
Copy Download .nbib Format: NLM
A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes.

Clinical cancer research : an official journal of the American Association for Cancer Research

Calagua C, Ficial M, Jansen CS, Hirz T, Del Balzo L, Wilkinson S, Lake R, Ku AT, Voznesensky O, Sykes DB, Saylor PJ, Ye H, Signoretti S, Kissick H, Sowalsky AG, Balk SP, Einstein DJ.
PMID: 34168052
Clin Cancer Res. 2021 Sep 01;27(17):4836-4847. doi: 10.1158/1078-0432.CCR-21-0121. Epub 2021 Jun 24.

PURPOSE: A subset of primary prostate cancer expresses programmed death-ligand 1 (PD-L1), but whether they have a unique tumor immune microenvironment or genomic features is unclear.EXPERIMENTAL DESIGN: We selected PD-L1-positive high-grade and/or high-risk primary prostate cancer, characterized tumor-infiltrating lymphocytes...

Cite
Calagua C, Ficial M, Jansen CS, et al. A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes. Clin Cancer Res. 2021;27(17):4836-4847doi: 10.1158/1078-0432.CCR-21-0121.
Calagua, C., Ficial, M., Jansen, C. S., Hirz, T., Del Balzo, L., Wilkinson, S., Lake, R., Ku, A. T., Voznesensky, O., Sykes, D. B., Saylor, P. J., Ye, H., Signoretti, S., Kissick, H., Sowalsky, A. G., Balk, S. P., & Einstein, D. J. (2021). A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(17), 4836-4847. https://doi.org/10.1158/1078-0432.CCR-21-0121
Calagua, Carla, et al. "A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,17 (2021): 4836-4847. doi: https://doi.org/10.1158/1078-0432.CCR-21-0121
Calagua C, Ficial M, Jansen CS, Hirz T, Del Balzo L, Wilkinson S, Lake R, Ku AT, Voznesensky O, Sykes DB, Saylor PJ, Ye H, Signoretti S, Kissick H, Sowalsky AG, Balk SP, Einstein DJ. A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes. Clin Cancer Res. 2021 Sep 01;27(17):4836-4847. doi: 10.1158/1078-0432.CCR-21-0121. Epub 2021 Jun 24. PMID: 34168052; PMCID: PMC8416924.
Copy Download .nbib Format: NLM
Plasticity in the Absence of NOTCH Uncovers a RUNX2-Dependent Pathway in Small Cell Lung Cancer.

Cancer research

Hong D, Knelson EH, Li Y, Durmaz YT, Gao W, Walton E, Vajdi A, Thai T, Sticco-Ivins M, Sabet AH, Jones KL, Schinzel AC, Bronson RT, Nguyen QD, Tolstorukov MY, Vivero M, Signoretti S, Barbie DA, Oser MG.
PMID: 34810201
Cancer Res. 2021 Nov 22; doi: 10.1158/0008-5472.CAN-21-1991. Epub 2021 Nov 22.

Neuroendocrine to non-neuroendocrine plasticity supports small cell lung cancer (SCLC) tumorigenesis and promotes immunogenicity. Approximately 20-25% of SCLCs harbor loss of function (LOF) NOTCH mutations. Previous studies demonstrated that NOTCH functions as a SCLC tumor suppressor, but can also...

Cite
Hong D, Knelson EH, Li Y, et al. Plasticity in the Absence of NOTCH Uncovers a RUNX2-Dependent Pathway in Small Cell Lung Cancer. Cancer Res. 2021;doi: 10.1158/0008-5472.CAN-21-1991.
Hong, D., Knelson, E. H., Li, Y., Durmaz, Y. T., Gao, W., Walton, E., Vajdi, A., Thai, T., Sticco-Ivins, M., Sabet, A. H., Jones, K. L., Schinzel, A. C., Bronson, R. T., Nguyen, Q. D., Tolstorukov, M. Y., Vivero, M., Signoretti, S., Barbie, D. A., & Oser, M. G. (2021). Plasticity in the Absence of NOTCH Uncovers a RUNX2-Dependent Pathway in Small Cell Lung Cancer. Cancer research, . https://doi.org/10.1158/0008-5472.CAN-21-1991
Hong, Deli, et al. "Plasticity in the Absence of NOTCH Uncovers a RUNX2-Dependent Pathway in Small Cell Lung Cancer." Cancer research vol. (2021). doi: https://doi.org/10.1158/0008-5472.CAN-21-1991
Hong D, Knelson EH, Li Y, Durmaz YT, Gao W, Walton E, Vajdi A, Thai T, Sticco-Ivins M, Sabet AH, Jones KL, Schinzel AC, Bronson RT, Nguyen QD, Tolstorukov MY, Vivero M, Signoretti S, Barbie DA, Oser MG. Plasticity in the Absence of NOTCH Uncovers a RUNX2-Dependent Pathway in Small Cell Lung Cancer. Cancer Res. 2021 Nov 22; doi: 10.1158/0008-5472.CAN-21-1991. Epub 2021 Nov 22. PMID: 34810201.
Copy Download .nbib Format: NLM
Development of a Histopathology Informatics Pipeline for Classification and Prediction of Clinical Outcomes in Subtypes of Renal Cell Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research

Marostica E, Barber R, Denize T, Kohane IS, Signoretti S, Golden JA, Yu KH.
PMID: 33722896
Clin Cancer Res. 2021 May 15;27(10):2868-2878. doi: 10.1158/1078-0432.CCR-20-4119. Epub 2021 Mar 15.

PURPOSE: Histopathology evaluation is the gold standard for diagnosing clear cell (ccRCC), papillary, and chromophobe renal cell carcinoma (RCC). However, interrater variability has been reported, and the whole-slide histopathology images likely contain underutilized biological signals predictive of genomic profiles.EXPERIMENTAL...

Cite
Marostica E, Barber R, Denize T, et al. Development of a Histopathology Informatics Pipeline for Classification and Prediction of Clinical Outcomes in Subtypes of Renal Cell Carcinoma. Clin Cancer Res. 2021;27(10):2868-2878doi: 10.1158/1078-0432.CCR-20-4119.
Marostica, E., Barber, R., Denize, T., Kohane, I. S., Signoretti, S., Golden, J. A., & Yu, K. H. (2021). Development of a Histopathology Informatics Pipeline for Classification and Prediction of Clinical Outcomes in Subtypes of Renal Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(10), 2868-2878. https://doi.org/10.1158/1078-0432.CCR-20-4119
Marostica, Eliana, et al. "Development of a Histopathology Informatics Pipeline for Classification and Prediction of Clinical Outcomes in Subtypes of Renal Cell Carcinoma." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,10 (2021): 2868-2878. doi: https://doi.org/10.1158/1078-0432.CCR-20-4119
Marostica E, Barber R, Denize T, Kohane IS, Signoretti S, Golden JA, Yu KH. Development of a Histopathology Informatics Pipeline for Classification and Prediction of Clinical Outcomes in Subtypes of Renal Cell Carcinoma. Clin Cancer Res. 2021 May 15;27(10):2868-2878. doi: 10.1158/1078-0432.CCR-20-4119. Epub 2021 Mar 15. PMID: 33722896.
Copy Download .nbib Format: NLM
Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research

Denize T, Farah S, Cimadamore A, Faifel A, Walton E, Sticco-Ivins MA, Labaki C, Braun DA, Sun M, Wang E, Xie W, Choueiri TK, Signoretti S.
PMID: 34921022
Clin Cancer Res. 2021 Dec 17; doi: 10.1158/1078-0432.CCR-21-3088. Epub 2021 Dec 17.

PURPOSE: Antiangiogenic VEGF receptor (VEGFR) inhibitors are approved for metastatic clear cell renal cell carcinoma (mccRCC) and their efficacy is higher in high angiogenic tumors. As cabozantinib inhibits multiple tyrosine kinase receptors, including VEGFRs, we tested whether markers of...

Cite
Denize T, Farah S, Cimadamore A, et al. Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial. Clin Cancer Res. 2021;doi: 10.1158/1078-0432.CCR-21-3088.
Denize, T., Farah, S., Cimadamore, A., Faifel, A., Walton, E., Sticco-Ivins, M. A., Labaki, C., Braun, D. A., Sun, M., Wang, E., Xie, W., Choueiri, T. K., & Signoretti, S. (2021). Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, . https://doi.org/10.1158/1078-0432.CCR-21-3088
Denize, Thomas, et al. "Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial." Clinical cancer research : an official journal of the American Association for Cancer Research vol. (2021). doi: https://doi.org/10.1158/1078-0432.CCR-21-3088
Denize T, Farah S, Cimadamore A, Faifel A, Walton E, Sticco-Ivins MA, Labaki C, Braun DA, Sun M, Wang E, Xie W, Choueiri TK, Signoretti S. Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial. Clin Cancer Res. 2021 Dec 17; doi: 10.1158/1078-0432.CCR-21-3088. Epub 2021 Dec 17. PMID: 34921022.
Copy Download .nbib Format: NLM
p63+ ureteric bud tip cells are progenitors of intercalated cells.

JCI insight

El-Dahr SS, Li Y, Liu J, Gutierrez E, Hering-Smith KS, Signoretti S, Pignon JC, Sinha S, Saifudeen Z.
PMID: 28469077
JCI Insight. 2017 May 04;2(9). doi: 10.1172/jci.insight.89996. eCollection 2017 May 04.

During renal branching morphogenesis, ureteric bud tip cells (UBTC) serve as the progenitor epithelium for all cell types of the collecting duct. While the transcriptional circuitry of ureteric bud (UB) branching has been intensively studied, the transcriptional control of...

Cite
El-Dahr SS, Li Y, Liu J, et al. p63+ ureteric bud tip cells are progenitors of intercalated cells. JCI Insight. 2017;2(9)doi: 10.1172/jci.insight.89996.
El-Dahr, S. S., Li, Y., Liu, J., Gutierrez, E., Hering-Smith, K. S., Signoretti, S., Pignon, J. C., Sinha, S., & Saifudeen, Z. (2017). p63+ ureteric bud tip cells are progenitors of intercalated cells. JCI insight, 2(9), . https://doi.org/10.1172/jci.insight.89996
El-Dahr, Samir S, et al. "p63+ ureteric bud tip cells are progenitors of intercalated cells." JCI insight vol. 2,9 (2017). doi: https://doi.org/10.1172/jci.insight.89996
El-Dahr SS, Li Y, Liu J, Gutierrez E, Hering-Smith KS, Signoretti S, Pignon JC, Sinha S, Saifudeen Z. p63+ ureteric bud tip cells are progenitors of intercalated cells. JCI Insight. 2017 May 04;2(9). doi: 10.1172/jci.insight.89996. eCollection 2017 May 04. PMID: 28469077; PMCID: PMC5414549.
Copy Download .nbib Format: NLM
Methods and outcomes of screening for pancreatic adenocarcinoma in high-risk individuals.

World journal of gastrointestinal endoscopy

Capurso G, Signoretti M, Valente R, Arnelo U, Lohr M, Poley JW, Delle Fave G, Del Chiaro M.
PMID: 26240684
World J Gastrointest Endosc. 2015 Jul 25;7(9):833-42. doi: 10.4253/wjge.v7.i9.833.

Pancreatic ductal adenocarcinoma (PDAC) is a lethal neoplasia, for which secondary prevention (i.e., screening) is advisable for high-risk individuals with "familiar pancreatic cancer" and with other specific genetic syndromes (Peutz-Jeghers, p16, BRCA2, PALB and mismatch repair gene mutation carriers)....

Cite
Capurso G, Signoretti M, Valente R, et al. Methods and outcomes of screening for pancreatic adenocarcinoma in high-risk individuals. World J Gastrointest Endosc. 2015;7(9):833-42doi: 10.4253/wjge.v7.i9.833.
Capurso, G., Signoretti, M., Valente, R., Arnelo, U., Lohr, M., Poley, J. W., Delle Fave, G., & Del Chiaro, M. (2015). Methods and outcomes of screening for pancreatic adenocarcinoma in high-risk individuals. World journal of gastrointestinal endoscopy, 7(9), 833-42. https://doi.org/10.4253/wjge.v7.i9.833
Capurso, Gabriele, et al. "Methods and outcomes of screening for pancreatic adenocarcinoma in high-risk individuals." World journal of gastrointestinal endoscopy vol. 7,9 (2015): 833-42. doi: https://doi.org/10.4253/wjge.v7.i9.833
Capurso G, Signoretti M, Valente R, Arnelo U, Lohr M, Poley JW, Delle Fave G, Del Chiaro M. Methods and outcomes of screening for pancreatic adenocarcinoma in high-risk individuals. World J Gastrointest Endosc. 2015 Jul 25;7(9):833-42. doi: 10.4253/wjge.v7.i9.833. PMID: 26240684; PMCID: PMC4515417.
Copy Download .nbib Format: NLM
In Reply.

The oncologist

de Velasco G, Culhane AC, Heng DYC, Signoretti S, Choueiri TK.
PMID: 28894018
Oncologist. 2017 Dec;22(12):1561. doi: 10.1634/theoncologist.2017-0283. Epub 2017 Sep 11.

No abstract available.

Cite
de Velasco G, Culhane AC, Heng DYC, et al. In Reply. Oncologist. 2017;22(12):1561doi: 10.1634/theoncologist.2017-0283.
de Velasco, G., Culhane, A. C., Heng, D. Y. C., Signoretti, S., & Choueiri, T. K. (2017). In Reply. The oncologist, 22(12), 1561. https://doi.org/10.1634/theoncologist.2017-0283
de Velasco, Guillermo, et al. "In Reply." The oncologist vol. 22,12 (2017): 1561. doi: https://doi.org/10.1634/theoncologist.2017-0283
de Velasco G, Culhane AC, Heng DYC, Signoretti S, Choueiri TK. In Reply. Oncologist. 2017 Dec;22(12):1561. doi: 10.1634/theoncologist.2017-0283. Epub 2017 Sep 11. PMID: 28894018; PMCID: PMC5728026.
Copy Download .nbib Format: NLM
Endoscopy-guided ablation of pancreatic lesions: Technical possibilities and clinical outlook.

World journal of gastrointestinal endoscopy

Signoretti M, Valente R, Repici A, Delle Fave G, Capurso G, Carrara S.
PMID: 28250896
World J Gastrointest Endosc. 2017 Feb 16;9(2):41-54. doi: 10.4253/wjge.v9.i2.41.

Endoscopic ultrasound (EUS) and endoscopic retrograde cholangiopancreatography (ERCP)-guided ablation procedures are emerging as a minimally invasive therapeutic alternative to radiological and surgical treatments for locally advanced pancreatic cancer (LAPC), pancreatic neuroendocrine tumours (PNETs), and pancreatic cystic lesions (PCLs). The...

Cite
Signoretti M, Valente R, Repici A, et al. Endoscopy-guided ablation of pancreatic lesions: Technical possibilities and clinical outlook. World J Gastrointest Endosc. 2017;9(2):41-54doi: 10.4253/wjge.v9.i2.41.
Signoretti, M., Valente, R., Repici, A., Delle Fave, G., Capurso, G., & Carrara, S. (2017). Endoscopy-guided ablation of pancreatic lesions: Technical possibilities and clinical outlook. World journal of gastrointestinal endoscopy, 9(2), 41-54. https://doi.org/10.4253/wjge.v9.i2.41
Signoretti, Marianna, et al. "Endoscopy-guided ablation of pancreatic lesions: Technical possibilities and clinical outlook." World journal of gastrointestinal endoscopy vol. 9,2 (2017): 41-54. doi: https://doi.org/10.4253/wjge.v9.i2.41
Signoretti M, Valente R, Repici A, Delle Fave G, Capurso G, Carrara S. Endoscopy-guided ablation of pancreatic lesions: Technical possibilities and clinical outlook. World J Gastrointest Endosc. 2017 Feb 16;9(2):41-54. doi: 10.4253/wjge.v9.i2.41. PMID: 28250896; PMCID: PMC5311472.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 64 entries